

Follow-up Formula Consumption in 3- to 4-Year-Olds and Respiratory Infections: An RCT

AUTHORS: Fei Li, MD, PhD,^a Xingming Jin, MD,^a Bryan Liu, MD,^b Weihong Zhuang, MS,^b and Deolinda Scalabrin, MD, PhD^b

^aDevelopmental and Behavioral Pediatric Department, Shanghai Children's Medical Center, Shanghai Jiaotong University School of Medicine, Shanghai, China; and ^bClinical Research, Department of Medical Affairs, Mead Johnson Nutrition, Evansville, Indiana

KEY WORDS

DHA, prebiotics, yeast β -glucan, acute respiratory infection, children

ABBREVIATIONS

ARI—acute respiratory infection
DHA—docosahexaenoic acid
FUF—follow-up formula
GOS—galacto-oligosaccharides
IL—interleukin
PDX—polydextrose
TGF—tumor growth factor
WBC—white blood cell

Dr Li conceptualized and designed the study, supervised data collection, interpreted the data, and reviewed and revised the manuscript; Dr Jin conceptualized and designed the study, supervised data collection, and reviewed the manuscript; Dr Liu conceptualized and designed the study, coordinated the data collection and analysis, interpreted the data, and reviewed and revised the manuscript; Ms Zhuang analyzed and interpreted the data and reviewed and revised the manuscript; Dr Scalabrin conceptualized and designed the study, analyzed and interpreted the data, and reviewed and revised the manuscript; and all authors approved the final manuscript.

This trial has been registered at www.clinicaltrials.gov (NCT01488435).

www.pediatrics.org/cgi/doi/10.1542/peds.2013-3598

doi:10.1542/peds.2013-3598

Accepted for publication Mar 10, 2014

Address correspondence to Deolinda Scalabrin, MD, PhD, 2400 West Lloyd Expressway, B201, Evansville, IN, 47721. E-mail: deolinda.scalabrin@mjn.com

(Continued on last page)



WHAT'S KNOWN ON THIS SUBJECT: Inadequate nutrient intake can compromise a child's nutritional status, which may affect immune function. Improving dietary intake via a follow-up formula may support appropriate immune responses and improve a child's ability to resist infection.



WHAT THIS STUDY ADDS: Children who consumed an experimental follow-up formula had fewer episodes and shorter duration of acute respiratory infections, as well as less antibiotic treatment, and fewer days missed of day care due to illness.

abstract

OBJECTIVE: Children are vulnerable to diet inadequacies, which may affect immune function. Our objective was to determine if a follow-up formula (FUF) containing DHA, the prebiotics PDX and GOS, and yeast β -glucan affects incidence of respiratory infections and diarrheal disease in healthy children.

METHODS: In a double-blind, randomized, controlled, prospective trial, 3-4 year old children were fed 3 servings per day of either a FUF with 25 mg DHA, 1.2 g PDX/GOS, and 8.7 mg yeast β -glucan per serving or an unfortified, cow's milk-based beverage (control) for 28 weeks. Fecal and blood samples were collected to assess immune markers and iron/zinc status. Incidence of acute respiratory infections (ARI), diarrheal disease, and antibiotic treatment were obtained from medical records.

RESULTS: The FUF group had fewer episodes and shorter duration of ARI (mean days [SE]; control = 4.3 [0.2]; FUF = 3.5 [0.2]; $P = .007$), less antibiotic use (n [%]; control = 21 [14%]; FUF = 8 [5%]; $P = .01$), and fewer missed days of day care due to illness. No diarrheal disease was diagnosed in either group. The FUF group had higher interleukin-10 and white blood cell count at the end of the study. There were no differences in hemoglobin, serum ferritin and zinc, or fecal secretory immunoglobulin A.

CONCLUSIONS: Daily consumption of a FUF was associated with fewer episodes and shorter duration of ARI, as well as less antibiotic use. The children who consumed the FUF had increased interleukin-10 and white blood cells, suggesting an antiinflammatory mechanism and/or an increase of effector immune cells. *Pediatrics* 2014;133:e1533–e1540

Children experience rapid growth and are vulnerable to diet inadequacy, which may affect immune function.^{1,2} The transition from a diet of human milk and/or infant formula to a diet consisting of cow's milk, nonmilk beverages, and solid foods may compromise a child's nutritional status.³ Much of the current understanding of nutritional impact on immune outcomes derives from animal studies, which are easily controlled for specific dietary components or from populations whose nutrient deficiencies are endemic.⁴ A systematic review of studies on diets of well-nourished children <5 years of age from developed countries identified a prevalence of incomplete adherence to dietary guidelines, indicating that there is room for improvement.⁵

Docosahexaenoic acid (DHA) has been associated with improved immune outcomes and fewer respiratory infections in infants and children.^{6–9} Previous studies of children <6 years of age in the United States have reported inadequate intake of DHA and corresponding low DHA status.^{7,10} In one study, children who consumed a cow's milk-based formula supplemented with DHA had improved DHA status and fewer respiratory illnesses, compared with children consuming unsupplemented formula.⁷ Dietary components, such as prebiotic oligosaccharides, can also influence host immune responses.^{11,12} Prebiotics may promote an increase in beneficial gut bacteria such as bifidobacteria^{13,14} and support respiratory and intestinal health.^{15–17} Another nutrient with immunomodulatory properties is yeast β -glucan, a polysaccharide isolated from the cell wall of *Saccharomyces cerevisiae*.¹⁸ Consumption of yeast β -glucan has been associated with fewer symptoms of acute respiratory infection (ARI) in healthy adults.^{19–21} A β -glucan from a different fungal source was reported to

promote an increase of blood NK lymphocytes and fewer ARIs in children with recurrent ARIs.²² However, no data on immune benefits of dietary intake of yeast β -glucan in children is currently available.

Respiratory infections, followed by diarrhea, are the leading cause of morbidity and mortality among children <5 years of age in China and worldwide.²³ Furthermore, diarrhea can compromise the nutritional status and be a risk factor for respiratory infections.²⁴ Our objective was to evaluate whether a follow-up formula (FUF) enriched with DHA, a prebiotic blend of polydextrose (PDX) and galacto-oligosaccharides (GOS), and yeast β -glucan has an effect on the incidence of ARI and/or diarrheal disease in healthy children attending day care in China.

METHODS

Population

Children (aged 3–4 years) who had been attending day care for up to 3 months and were consuming cow's milk or a cow's milk-based beverage before randomization were eligible. Exclusion criteria were (1) consumption of prebiotics or probiotics in the 15 days before randomization; (2) diarrhea or ARI during the 48 hours before randomization; (3) a z score of weight-for-height < -3; or (4) serious concurrent illness. The study sponsor (Mead Johnson Nutrition, Evansville, IN) provided a computer-generated randomization schedule and sealed consecutively numbered envelopes to the study site. Study formulas, designated by unique codes known only to the sponsor, were assigned by the study site to eligible children by opening the next sequential envelope. Product labels and envelopes were constructed to prevent unblinding. The study products were identical in odor, color, and flavor (vanilla). The study was conducted at a day care in Jinhua, Zhejiang Province, China

from November 2011 to May 2012. The Shanghai Nutrition Society institutional review board approved the protocol, and a parent/legal guardian provided signed informed consent before enrollment.

Design

In this double-blind, randomized, controlled, parallel-designed, prospective trial, children were fed an experimental FUF, according to the CODEX Alimentarius definition,²⁵ enriched with 25 mg DHA, 1.2 g blend of PDX/GOS (1:1 ratio), and 8.7 mg yeast β -glucan (Wellmune WGP, Biothera, Eagan, MN) per serving, or a nonenriched, cow's milk-based beverage (control). Previous studies have demonstrated health benefits of similar levels of DHA⁷ and PDX/GOS²⁶ in children. Because of the lack of published studies in children, the level of β -glucan was extrapolated from the efficacious range of daily intake in adults.^{20,21} Study products were given 3 times per day for 28 weeks. Each serving consisted of 40 g of powder mixed with 200 mL water. See Table 1 for study product nutrient composition.

Outcomes

The primary outcome was incidence of ARI and/or diarrheal disease. ARI was defined as upper respiratory infections, including common cold, pharyngitis, tonsillitis, otitis media, infectious sinusitis and rhinitis, and lower respiratory infections, including pneumonia, bronchiolitis, and bronchitis. Diarrheal disease was defined as ≥ 3 liquid/semiliquid stools in 24 hours with fever and/or vomiting and/or dehydration and compromised general status. Secondary outcomes included duration of ARI and diarrheal disease, systemic antibiotic treatment, allergic manifestations, days missed at day care due to illness, stool pattern, and growth. All children were referred to a single designated study clinic.

TABLE 1 Nutrient Composition of Study Formulas

Per 40 g Serving of Powder	Control	FUF
Energy, kcal	180	180
Protein, g	7.3	7.3
Fat, g	6.6	6.6
DHA, mg	—	25
Carbohydrate, g	23	23
Dietary fiber, g (1:1 ratio polydextrose/galactooligosaccharides)	—	1.2
Yeast β -1,3/1,6-glucans, mg	—	8.7
Vitamin A, IU	380	630
Vitamin D, IU	31	119
Vitamin E, IU	0.33	2.6
Vitamin K ₁ , mcg	0.41	9.5
Thiamine, mcg	57	210
Riboflavin, mcg	520	490
Vitamin B ₆ , mcg	42	183
Vitamin B ₁₂ , mcg	0.72	0.72
Niacin, mcg	144	2200
Folic acid, mcg	7.8	31
Pantothenic acid, mcg	770	1160
Biotin, mcg	5.4	4.7
Vitamin C, mg	2.4	29
Choline, mg	28	44
Calcium, mg	280	290
Phosphorus, mg	200	187
Magnesium, mg	25	26
Sodium, mg	97	96
Potassium, mg	400	420
Chloride, mg	330	320
Iodine, mcg	13.4	15.2
Iron, mg	0.05	3.0
Zinc, mg	0.72	2.3
Manganese, mcg	5	19.2
Copper, mcg	4.8	82

—, indicates that formula did not contain nutrient.

Stool and blood samples were collected at baseline and at the end of study to assess stool parasites by direct microscopy, peripheral blood cell count, serum ferritin and zinc, and immune markers by enzyme-linked immunosorbent assay (fecal secretory immunoglobulin A and serum interleukin [IL]-10, tumor growth factor [TGF]- β 1, TGF- β 2, IL-4, and IFN- γ). Laboratory analyses were conducted by R&D Systems (Shanghai, China). Weight and height measurements were obtained at randomization and every 4 weeks thereafter and converted into z scores based on World Health Organization references.²⁷

Sample Size and Statistics

A sample size of 125 per group was needed to achieve 90% power, assuming

a control group proportion of 0.5 and a test group proportion of 0.3 at an α level of .05. The frequencies of ARI, diarrheal disease, or allergic manifestations, as well as number of missed days of day care due to illness, were compared with the Cochran-Mantel-Haenszel test. The average duration of ARI was analyzed by analysis of variance and antibiotic treatment and incidence of fecal parasites by Fisher's exact test. Fecal and serum immune markers, serum ferritin and zinc, and peripheral blood count values were compared by using Kruskal-Wallis test, whereas changes from baseline to end of study were analyzed by using analysis of covariance, with baseline values as covariates. Stool frequency and consistency and weight and height z scores were analyzed by using repeated measures analysis of variance.

RESULTS

Study Population and Clinical Outcomes

The study initially enrolled 310 children, and 264 completed the study. Reasons for discontinuation were participants' move to another city (control = 13; FUF = 19) or parental decision (control = 10; FUF = 4). Demographic and baseline characteristics (race, age, gender distribution, and anthropometric measures) were similar between groups, except weight-for-age z-scores of females (mean z score [SE]; control = 0.3 [0.1] vs FUF = 0.1 [0.1]; $P = .03$). During the study, height-for-age z-scores of females were higher in the control group compared to FUF at study week 28. Both genders in the two groups had an increase in weight-for-age and height-for-age z scores from baseline to end of study ($P < .001$). Weight-for-height z scores also increased (girls: 0.2 and 0.1–0.4 and 0.5; boys: 0.9 and 0.5–1.1 and 0.8, in controls and FUF, respectively; $P < .001$). Intake of study products was similar between groups.

Children consuming the FUF had fewer episodes and shorter average duration of ARI compared with control, and fewer children in the FUF group were treated with systemic antibiotics (Table 2 and Fig 1). The mean duration of each antibiotic treatment was 3 days, and none of the children received more than a single course of antibiotics.

The FUF group missed fewer days of day care due to illness (Table 3). The median number of days absent was 0 for both groups (60%–70% missed no days due to illness), and the average number of days missed due to illness was 0.8 and 0.5 for control and FUF groups, respectively. The percentage of children who missed at least 1 day of day care due to illness was lower in the FUF group compared with control (29% vs 37%; absolute risk reduction = 0.08; number needed to treat = 13).

No lower respiratory infections were diagnosed, and no children were hospitalized during the study. Only 1 case of allergic manifestation (food allergy) was reported. No diarrheal disease was reported; however, diarrhea was to be confirmed using strict preestablished criteria, potentially excluding mild cases of diarrhea that could be of infectious origin. No differences in stool consistency or frequency between groups were observed.

Fecal/Blood Outcomes

Children consuming FUF had higher levels of serum IL-10 at 28 weeks compared with control. No differences were observed in fecal secretory immunoglobulin A, TGF- β 1, TGF- β 2, IL-4, and IFN- γ (Table 4). There were no differences

TABLE 2 Frequency of ARI During the 28-Week Study Period

	Number of ARI Episodes				<i>P</i>
	None	1	2	3	
Control, <i>n</i> (%)	73 (47)	68 (44)	11 (7)	2 (1)	.04
FUF, <i>n</i> (%)	90 (58)	58 (37)	8 (5)	0	




FIGURE 1

A, Average duration in days of ARI for those who had ARIs (Mean [SE]; control = 4.3 [0.2] days; FUF = 3.5 [0.2] days; $P = .007$). B, Participants (%) receiving systemic antibiotic treatment (n [%]; control = 21 [14%]; FUF = 8 [5%]; $P = .01$).

TABLE 3 Frequency of Day-Care Days Missed Due to Illness During the 28-Week Study Period

	Number of Days Missed							P
	None	1	2	3	4	5	6	
Control, n (%)	97 (63)	20 (13)	18 (12)	12 (8)	3 (2)	2 (1)	2 (1)	.01
FUF, n (%)	111 (71)	25 (16)	11 (7)	7 (4)	2 (1)	0	0	

in serum ferritin and zinc, hemoglobin, hematocrit, or red blood cells (Table 5). Based on World Health Organization criteria for anemia (hemoglobin <11.0 g/dL) and iron deficiency (ferritin < 12.0 ng/mL),²⁸ the overall study population had a prevalence of anemia of 65% ($n = 202$) and 58% ($n = 153$) and iron deficiency of 41% ($n = 108$) and 42% ($n = 104$) at onset and end of study, respectively. There were no differences in the number of participants who remained anemic or iron deficient at the end of the study. Children consuming FUF had higher white blood cell (WBC) count at 28 weeks; a difference in the change in WBC from baseline between groups was also observed (Table 6). The only fecal parasites detected were *Blastocystis hominis* (27%, both control and FUF groups, at baseline; 18%, control, and 24%, FUF, at end of study) and *Ascaris lumbricoides* (only 1 participant in control group, at baseline). No antiparasite treatment was given during the study, and there were no differences in fecal parasites.

DISCUSSION

We report that children who consumed an FUF had fewer episodes and shorter duration of ARI, fewer systemic antibiotic treatments, and missed fewer days at day care due to illness compared with children who consumed an unfortified, cow's-milk based beverage. They also had higher serum levels of IL-10, as well as higher blood leukocytes. No occurrence of diarrheal disease was reported during the study.

ARI was identified as causing symptoms 22% to 40% of the time during a 2-year observation period in an epidemiologic study in 0-5 year old children from 10 countries, including two in Asia.²⁹ The number of episodes of ARI observed in the current study (Table 2) was proportionally lower than the number of episodes previously reported in 3- to 4-year-old children in the United States (average 4.7 episodes per year).³⁰ We are not aware of data on frequency of ARI in 3- to 4-year-old children in China to which our findings could be com-

pared. ARI is commonly diagnosed in both children who stay at home and those who attend day care; however, it is reported to be more frequent in the latter, especially among those who attend day care during the first year of life.^{31,32} The impact of late day care exposure (>2 years of age) on ARI at 3- to 4-years of age was reported in 2 distinct populations in the United States and the Netherlands, with divergent outcomes of either decreasing³² or increasing³³ ARI frequency. Regardless of whether ARI frequency was higher or lower than expected in our control group, it was significantly lower in the FUF compared with the control group, with potential repercussions in overall health and development.

In the United States, rhinovirus has been identified as the most common cause of ARI in children requiring physician consultation.³⁰ Likewise, recent data from China indicate that the most common ARI agents in children were respiratory syncytial virus, parainfluenza virus, and rhinovirus.³⁴ All ARIs diagnosed in our study were upper respiratory infections, which are usually less severe and have shorter duration than lower respiratory infections. The mean duration of ARI reported in the control group (4.3 days) was

TABLE 4 Comparison of Immune Markers Between Study Groups^a

	Control Median (IQR ^b)	FUF Median (IQR ^b)	P
Fecal Secretory IgA, mg/dL			
Baseline	151 (59–324)	199 (70–144)	.19
Week 28	449 (227–760)	511 (234–788)	.30
Baseline to wk 28	237 (84–432)	238 (103–450)	.38
IL-10, pg/mL			
Baseline	3.9 (≤3.2–7.5)	4.4 (≤3.4–7.2)	.62
Week 28	5.8 (4.1–8.0)	6.5 (4.8–9.4)	.04
Baseline to wk 28	0.5 (–1.0 to 3.0)	1.3 (–1.0 to 4.0)	.24
TGF-β1, pg/mL			
Baseline	24042 (20179–29814)	24040 (19807–27696)	.38
Week 28	22319 (18021–29588)	22967 (17743–30973)	.52
Baseline to wk 28	–2467 (–8184 to 5878)	1340 (–5119 to 7769)	.13
TGF-β2, pg/mL			
Baseline	338.3 (<243.4–521.5)	323.8 (<243.4–420.1)	.40
Week 28	305.3 (<243.4–443.6)	362.9 (<243.4–502.8)	.26
Baseline to week 28	–31.2 (–66.0 to 0.0)	–8.9 (–45.0–0.0)	.39
IL-4, pg/mL^c			
Baseline	<1.6 (<1.6–<1.6)	<1.6 (<1.6–<1.6)	1.00
Week 28	<1.6 (<1.6–<1.6)	<1.6 (<1.6–<1.6)	.15
IFN-γ, pg/mL^c			
Baseline	<15.6 (<15.6–<15.6)	<15.6 (<15.6–<15.6)	.99
Week 28	<15.6 (<15.6–<15.6)	<15.6 (<15.6–<15.6)	.30

Ig, immunoglobulin; IQR, interquartile range.

^a All markers except fecal secretory IgA were measured in serum.

^b IQR = 25%–75% interquartile range.

^c Changes from baseline to Week 28 not analyzed because most of the samples were under detection limit.

TABLE 5 Comparison of Zinc and Iron Status Between Study Groups

	Control Median (IQR ^a)	FUF Median (IQR ^a)	P
Serum zinc, μmol/L			
Baseline	22.1 (18.1–25.6)	22.2 (18.0–25.7)	.88
Week 28	23.7 (21.3–28.5)	24.4 (21.6–28.0)	.45
Baseline to wk 28	3.4 (–2.0 to 11.0)	3.5 (–2.0 to 8.0)	.85
Serum ferritin, ng/mL			
Baseline	13.3 (<10–24.2)	15.4 (<10–25.0)	.27
Week 28	13.8 (<10–21.9)	16.8 (<10–26.7)	.10
Baseline to wk 28	0.0 (–4.0 to 3.0)	0.0 (–4.0 to 9.0)	.31
Hemoglobin, g/dL			
Baseline	10.6 (10.2–11.2)	10.7 (10.1–11.1)	.52
Week 28	10.9 (10.4–11.3)	10.8 (10.4–11.3)	.96
Baseline to wk 28 ^b	0.1 (0.06)	0.2 (0.06)	.32
Hematocrit, %			
Baseline	32.3 (30.9–33.8)	32.4 (30.8–33.5)	.66
Week 28	33.4 (31.8–35.1)	33.3 (32–34.9)	.90
Baseline to wk 28 ^b	0.9 (0.19)	1.1 (0.19)	.42
Red blood cells, × 10⁹/mL			
Baseline	4.0 (3.8–4.1)	3.9 (3.7–4.1)	.33
Week 28	4.0 (3.8–4.2)	4.0 (3.8–4.1)	.25
Baseline to wk 28 ^b	0.0 (0.02)	0.0 (0.02)	.80

^a IQR = 25% to 75% interquartile range.

^b Changes from baseline to study week 28 were analyzed by using analysis of covariance, with baseline values as the covariate; the values listed are Adjusted Mean (SE).

shorter than the duration of upper respiratory infections reported in a previous study in 2- to 3-year-old day-care children (7.8 days); this difference may be explained by the different age range in the 2 studies, because shorter

duration of respiratory infection has been demonstrated as a child grows older.³⁵ Notably, the decrease in duration of ARI in the FUF group when compared with control (mean of 0.8 days) is of a similar magnitude as the

decrease in duration reported with use of antiviral treatment (1 day).³⁶ A dietary approach, however, does not have the risks of adverse events linked to the use of antiviral drugs.³⁷

The prevalence of allergic diseases reported in 3- to 4-year-old children in China is lower than the prevalence in some Western countries, especially for asthma (2.2%–9.7%), although it is increasing.³⁸ It has been a matter of debate whether exposure to early infections is a risk or a protective factor against later allergic disease. The existence of siblings or day-care attendance are proxy variables for early exposure to infections and have been identified as protective against allergy and asthma at 3 to 4 years of age, according to the hygiene hypothesis.^{39,40} Contrary to the hygiene hypothesis, some studies showed that attending day care in the first year of life was a risk factor for wheezing and allergic rhinitis at 1 to 4 years of age^{32,33,41}; likewise, ARI caused by rhinovirus have been identified as the strongest predictor of wheezing in the third year of life.⁴² In the current study, the absence of asthma-like wheezing and allergy symptoms (only 1 child with food allergy reported) is noteworthy. This may be partially explained by the low prevalence of childhood allergy in China and seems to conflict with the hygiene hypothesis because both groups had low exposure to siblings and no early day-care attendance that could explain the low incidence of allergy. Nonetheless, our findings are consistent with data showing that absence of siblings or of early day-care exposure are associated with decreased wheezing and allergy at 3 to 4 years of age.^{32,33}

A notably high prevalence of anemia was observed in the overall study population. Anemia was higher than the 48% prevalence reported in preschool children in Asia⁴³ (65% at start and 58% at end of study), with no response to

TABLE 6 Comparison of WBCs and Platelets Between Study Groups^a

	Control Median (IQR ^b)	FUF Median (IQR ^b)	P
WBC, ×10 ⁶ /mL			
Baseline	8.0 (7.0–9.2)	8.1 (6.9–9.5)	.93
Week 28	7.7 (6.6–9.3)	8.5 (7.2–9.7)	.05
Baseline to wk 28	−0.4 (0.2)	0.1 (0.2)	.01
Neutrophils, %			
Baseline	52.6 (46.8–59.6)	52.2 (46.7–57.3)	.44
Week 28	49.5 (42.1–55.5)	50.3 (45.6–56.3)	.19
Baseline to wk 28	−6.0 (1.1)	−3.1 (1.1)	.07
Lymphocytes, %			
Baseline	41.2 (34.1–46.8)	41 (36.6–47.5)	.44
Week 28	42.2 (36.6–50.5)	42.3 (37–46.7)	.34
Baseline to wk 28	3.6 (1.1)	2.3 (1.1)	.40
Platelets, ×10 ⁶ /mL			
Baseline	282 (244–315)	280.5 (241–317.5)	.93
Week 28	281 (246–328)	283 (249–319)	.81
Baseline to wk 28	3.7 (4.2)	0.1 (4.1)	.54

^a Changes from baseline to week 28 were analyzed by using analysis of covariance, with baseline values as the covariate; the values listed are adjusted mean (SE).

^b IQR = 25%–75% interquartile range.

the supplemental amount of iron in the FUF (9 mg/day), suggesting that this dose was too low compared with the recommended dose to treat anemia (3 mg/kg/day)²⁸ and/or other causes of anemia could be operating. Similarly, we observed a 41% prevalence of iron deficiency in the study population, which is higher than a prevalence of 24%, reported in a mixed urban and rural preschool cohort in China,⁴⁴ and was not reverted by the FUF, remaining at 42% at the end of the study. Zinc status was normal, with no differences between groups at onset and end of study. Given the contribution of direct transmission of pathogens to the prevalence of ARI in children in a day care, as well as the limited ability to reduce incidence of ARI through infection control techniques,⁴⁵ alternative measures such as nutritional supplementation should be considered. Cow's milk is a regularly consumed beverage after 1 year of age. A recent survey in France showed that 1- to 2-year-old children consuming regular cow's milk were at increased risk of insufficient intake of nutrients, such as essential fatty acid, iron, and vitamins C and D, compared with those consuming a fortified cow's milk-based formula.⁴⁶ The higher amount of

micronutrients in FUF compared with the control may have contributed to improved respiratory health in our study, with DHA, prebiotics, and yeast β -glucan contributing to specific immune effects. To identify the contribution of individual nutrients to the respiratory findings, subsequent studies are warranted.

The higher levels of IL-10 in the FUF group suggest an antiinflammatory mechanism, and the higher WBC values in the FUF group, albeit within the normal range, suggest an increase in effector immune cells, both of which may have contributed to decreased ARIs. DHA can reduce production of pro-inflammatory cytokines,^{47,48} and antiinflammatory effects have been demonstrated for DHA and its metabolites such as resolvins and protectins.⁴⁹ For example, protectin D1 (PD1) reduces allergic pulmonary inflammation,⁵⁰ and inhibits production of pro-inflammatory cytokines such as IL-1 β , TNF α , and IFN γ .⁴⁹ DHA can also exert antiinflammatory effects via G protein-coupled receptors in macrophages, thereby inhibiting pro-inflammatory signaling pathways.⁵¹ Our data are also consistent with a study in which subcutaneous injections of yeast β -glucan for 8 weeks increased serum

IL-10 levels and improved asthma symptoms in children.⁵² Additionally, administration of a combination of colloidal silver and β -glucan relieved viral rhinitis and ARI in children.⁵³ β -glucan polymers are pathogen-associated molecular patterns that are recognized by multiple pattern recognition receptors expressed in various cells of the innate immune system, including monocyte/macrophage and neutrophil.⁵⁴ By binding to those receptors, β -glucan initiates a cascade of events that results in enhanced macrophage and neutrophil function and increased microbial clearance.^{55,56} Our observation of an increase in WBCs seems consistent with the mechanisms described for β -glucan and with the previous reporting of increased blood natural killer lymphocytes in children receiving fungal β -glucan.^{22,57} To our knowledge, this is the first study reporting a potential impact of oral intake of yeast β -glucan on immune markers in healthy children. It is to be noted that the high prevalence of *Blastocystis hominis* in the current study (up to 27%) is consistent with reports of up to 33% prevalence of this parasite in China.⁵⁸ Data in vitro suggest that *Blastocystis hominis* may induce inflammatory cytokines in the host's gut epithelial cells.⁵⁹ No differences in the prevalence of this parasite were seen between groups at the end of the study. Because no antiparasite treatment was given during the study, we suggest that immune active ingredients in the FUF such as yeast β -glucan and DHA have no detectable action against this parasite.

Normal diet often contains naturally occurring prebiotics, β -glucan, and DHA. However, the levels of these components vary according to the quality of the diet and may not be sufficient to promote measurable health benefits. There is currently no agreement on the optimal diet for young children or on what impact improved diet would have

in those children whose dietary intake meets the minimal nutrient requirements but may not be of the highest quality necessary to promote improved health. The findings in the current study suggest that regular consumption of a follow-up formula enriched with DHA, the prebiotics PDX and GOS,

yeast β -glucan, and essential nutrients may improve respiratory health.

ACKNOWLEDGMENTS

We thank the children and parents who participated in this study, and the day-care staff for their collaboration. We thank the Sprim China team, Charlie

Zhang, MD, Kelly Zhang, RN, MS, and Shirley Lu, BS, for study operation. We thank the R&D Systems China team, Wendy Shao, PhD and Maren May, MS, for laboratory analyses. We thank Paul Strong, PhD for writing assistance, and Cheryl Harris, MS for assistance with the statistical analysis/interpretation.

REFERENCES

1. Calder PC. Feeding the immune system. *Proc Nutr Soc.* 2013;72(3):299–309
2. Field CJ, Johnson IR, Schley PD. Nutrients and their role in host resistance to infection. *J Leukoc Biol.* 2002;71(1):16–32
3. Briefel RR, Reidy K, Karwe V, Devaney B. Feeding infants and toddlers study: Improvements needed in meeting infant feeding recommendations. *J Am Diet Assoc.* 2004;104(1 suppl 1):s31–s37
4. Bhutta ZA, Black RE, Brown KH, et al. Prevention of diarrhea and pneumonia by zinc supplementation in children in developing countries: pooled analysis of randomized controlled trials. Zinc Investigators' Collaborative Group. *J Pediatr.* 1999;135(6):689–697
5. Smithers LG, Golley RK, Brazionis L, Lynch JW. Characterizing whole diets of young children from developed countries and the association between diet and health: a systematic review. *Nutr Rev.* 2011;69(8):449–467
6. Hageman JH, Hooyenga P, Diersen-Schade DA, Scalabrin DM, Wichers HJ, Birch EE. The impact of dietary long-chain polyunsaturated fatty acids on respiratory illness in infants and children. *Curr Allergy Asthma Rep.* 2012;12(6):564–573
7. Minns LM, Kerling EH, Neely MR, et al. Toddler formula supplemented with docosahexaenoic acid (DHA) improves DHA status and respiratory health in a randomized, double-blind, controlled trial of US children less than 3 years of age. *Prostaglandins Leukot Essent Fatty Acids.* 2010;82(4–6):287–293
8. Pastor N, Soler B, Mitmesser SH, Ferguson P, Lifschitz C. Infants fed docosahexaenoic acid- and arachidonic acid-supplemented formula have decreased incidence of bronchiolitis/bronchitis the first year of life. *Clin Pediatr (Phila).* 2006;45(9):850–855
9. Birch EE, Khoury JC, Berseth CL, et al. The impact of early nutrition on incidence of allergic manifestations and common respiratory illnesses in children. *J Pediatr.* 2010;156(6):902–906, 906e1
10. Ervin RB, Wright JD, Wang CY, Kennedy-Stephenson J. Dietary intake of fats and fatty acids for the United States population: 1999–2000. *Adv Data.* 2004;(348):1–6
11. Scholtens PA, Alliet P, Raes M, et al. Fecal secretory immunoglobulin A is increased in healthy infants who receive a formula with short-chain galacto-oligosaccharides and long-chain fructo-oligosaccharides. *J Nutr.* 2008;138(6):1141–1147
12. Vulevic J, Juric A, Tzortzis G, Gibson GR. A mixture of trans-galactooligosaccharides reduces markers of metabolic syndrome and modulates the fecal microbiota and immune function of overweight adults. *J Nutr.* 2013;143(3):324–331
13. Fanaro S, Marten B, Bagna R, et al. Galacto-oligosaccharides are bifidogenic and safe at weaning: a double-blind randomized multicenter study. *J Pediatr Gastroenterol Nutr.* 2009;48(1):82–88
14. Scalabrin DM, Mitmesser SH, Welling GW, et al. New prebiotic blend of polydextrose and galacto-oligosaccharides has a bifidogenic effect in young infants. *J Pediatr Gastroenterol Nutr.* 2012;54(3):343–352
15. Arslanoglu S, Moro GE, Boehm G. Early supplementation of prebiotic oligosaccharides protects formula-fed infants against infections during the first 6 months of life. *J Nutr.* 2007;137(11):2420–2424
16. Bruzzese E, Volpicelli M, Squeglia V, et al. A formula containing galacto- and fructo-oligosaccharides prevents intestinal and extra-intestinal infections: an observational study. *Clin Nutr.* 2009;28(2):156–161
17. Binns CW, Lee AH, Harding H, Gracey M, Barclay DV. The CUPDAY Study: prebiotic-probiotic milk product in 1–3-year-old children attending childcare centres. *Acta Paediatr.* 2007;96(11):1646–1650
18. Novak M, Vetvicka V. Beta-glucans, history, and the present: immunomodulatory aspects and mechanisms of action. *J Immunotoxicol.* 2008;5(1):47–57
19. Auinger A, Riede L, Bothe G, Busch R, Gruenewald J. Yeast (1,3)-(1,6)-beta-glucan helps to maintain the body's defence against pathogens: a double-blind, randomized, placebo-controlled, multicentric study in healthy subjects. *Eur J Nutr.* 2013;52(8):1913–1918
20. Talbott SM, Talbott JA. Baker's yeast beta-glucan supplement reduces upper respiratory symptoms and improves mood state in stressed women. *J Am Coll Nutr.* 2012;31(4):295–300
21. Talbott S, Talbott J. Effect of BETA 1, 3/1, 6 GLUCAN on upper respiratory tract infection symptoms and mood state in marathon athletes. *J Sports Sci Med.* 2009;8(4):509–515
22. Jesenak M, Majtan J, Rennerova Z, Kyselovic J, Banovcin P, Hrubisko M. Immunomodulatory effect of pleuran (β -glucan from *Pleurotus ostreatus*) in children with recurrent respiratory tract infections. *Int Immunopharmacol.* 2013;15(2):395–399
23. Black RE, Cousens S, Johnson HL, et al; Child Health Epidemiology Reference Group of WHO and UNICEF. Global, regional, and national causes of child mortality in 2008: a systematic analysis. *Lancet.* 2010;375(9730):1969–1987
24. Walker CL, Perin J, Katz J, Tielsch JM, Black RE. Diarrhea as a risk factor for acute lower respiratory tract infections among young children in low income settings. *J Glob Health.* 2013;3(1):010402
25. CODEX. *Codex Standard for Follow-Up Formula: Codex Stan 156-1987.* Geneva, Switzerland: Codex; 1987
26. Ribeiro TC, Costa-Ribeiro H Jr, Almeida PS, et al. Stool pattern changes in toddlers consuming a follow-on formula supplemented with polydextrose and galactooligosaccharides. *J Pediatr Gastroenterol Nutr.* 2012;54(2):288–290
27. World Health Organization Multicentre Growth Reference Study Group. WHO Child Growth Standards based on length/height, weight and age. *Acta Paediatr. Suppl.* 2006;450:76–85
28. World Health Organization. Iron deficiency anaemia: assessment, prevention and control: a guide for programme managers. WHO/NHD/0.13. Geneva, Switzerland: 2001
29. Selwyn BJ; Coordinated Data Group of BOSTID Researchers. The epidemiology of

- acute respiratory tract infection in young children: comparison of findings from several developing countries. *Rev Infect Dis*. 1990;12(suppl 8):S870–S888
30. Monto AS. Epidemiology of viral respiratory infections. *Am J Med*. 2002;112(suppl 6A):4S–12S
 31. Hurwitz ES, Gunn WJ, Pinsky PF, Schonberger LB. Risk of respiratory illness associated with day-care attendance: a nationwide study. *Pediatrics*. 1991;87(1):62–69
 32. Sun Y, Sundell J. Early daycare attendance increase the risk for respiratory infections and asthma of children. *J Asthma*. 2011;48(8):790–796
 33. Caudri D, Wijga A, Scholtens S, et al. Early daycare is associated with an increase in airway symptoms in early childhood but is no protection against asthma or atopy at 8 years. *Am J Respir Crit Care Med*. 2009;180(6):491–498
 34. Huang G, Yu D, Mao N, et al. Viral etiology of acute respiratory infection in Gansu Province, China, 2011. *PLoS ONE*. 2013;8(5):e64254
 35. Wald ER, Guerra N, Byers C. Upper respiratory tract infections in young children: duration of and frequency of complications. *Pediatrics*. 1991;87(2):129–133
 36. Hayden FG, Herrington DT, Coats TL, et al; Pleconaril Respiratory Infection Study Group. Efficacy and safety of oral pleconaril for treatment of colds due to picornaviruses in adults: results of 2 double-blind, randomized, placebo-controlled trials. *Clin Infect Dis*. 2003;36(12):1523–1532
 37. Shun-Shin M, Thompson M, Heneghan C, Perera R, Harnden A, Mant D. Neuraminidase inhibitors for treatment and prophylaxis of influenza in children: systematic review and meta-analysis of randomised controlled trials. *BMJ*. 2009;339:b3172
 38. Zhao J, Bai J, Shen K, et al. Self-reported prevalence of childhood allergic diseases in three cities of China: a multicenter study. *BMC Public Health*. 2010;10:551
 39. Cardoso MR, Cousens SN, de Góes Siqueira LF, Alves FM, D'Angelo LA. Crowding: risk factor or protective factor for lower respiratory disease in young children? *BMC Public Health*. 2004;4:19
 40. Infante-Rivard C, Amre D, Gautrin D, Malo JL. Family size, day-care attendance, and breastfeeding in relation to the incidence of childhood asthma. *Am J Epidemiol*. 2001;153(7):653–658
 41. Hagerhed-Engman L, Bornehag CG, Sundell J, Aberg N. Day-care attendance and increased risk for respiratory and allergic symptoms in preschool age. *Allergy*. 2006;61(4):447–453
 42. Lemanske RF Jr, Jackson DJ, Gangnon RE, et al. Rhinovirus illnesses during infancy predict subsequent childhood wheezing. *J Allergy Clin Immunol*. 2005;116(3):571–577
 43. McLean E, Cogswell M, Egli I, Wojdyla D, de Benoist B. Worldwide prevalence of anaemia, WHO Vitamin and Mineral Nutrition Information System, 1993–2005. *Public Health Nutr*. 2009;12(4):444–454
 44. Liu J, McCauley LA, Zhao Y, Zhang H, Pinto-Martin J; Jintan Cohort Study Group. Cohort Profile: The China Jintan Child Cohort Study. *Int J Epidemiol*. 2010;39(3):668–674
 45. Roberts L, Smith W, Jorm L, Patel M, Douglas RM, McGilchrist C. Effect of infection control measures on the frequency of upper respiratory infection in child care: a randomized, controlled trial. *Pediatrics*. 2000;105(4 Pt 1):738–742
 46. Ghisolfi J, Fantino M, Turck D, de Courcy GP, Vidailhet M. Nutrient intakes of children aged 1–2 years as a function of milk consumption, cows' milk or growing-up milk. *Public Health Nutr*. 2013;16(3):524–534
 47. Draper E, Reynolds CM, Canavan M, Mills KH, Loscher CE, Roche HM. Omega-3 fatty acids attenuate dendritic cell function via NF- κ B independent of PPAR γ . *J Nutr Biochem*. 2011;22(8):784–790
 48. van den Elsen L, Garssen J, Willemsen L. Long chain N-3 polyunsaturated fatty acids in the prevention of allergic and cardiovascular disease. *Curr Pharm Des*. 2012;18(16):2375–2392
 49. Serhan CN, Chiang N, Van Dyke TE. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. *Nat Rev Immunol*. 2008;8(5):349–361
 50. Levy BD, Kohli P, Gottinger K, et al. Protectin D1 is generated in asthma and dampens airway inflammation and hyperresponsiveness. *J Immunol*. 2007;178(1):496–502
 51. Oh DY, Talukdar S, Bae EJ, et al. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. *Cell*. 2010;142(5):687–698
 52. Sarinho E, Medeiros D, Schor D, et al. Production of interleukin-10 in asthmatic children after Beta-1-3-glucan. *Allergol Immunopathol (Madr)*. 2009;37(4):188–192
 53. Damiani V, Di Carlo M, Grappasonni G, Di Domenico R, Dominici P. Efficacy of a new medical device based on colloidal silver and carbosimetyl beta glucan in treatment of upper airways disease in children. *Minerva Pediatr*. 2011;63(5):347–354
 54. Rice PJ, Kelley JL, Kogan G, et al. Human monocyte scavenger receptors are pattern recognition receptors for (1 \rightarrow 3)-beta-D-glucans. *J Leukoc Biol*. 2002;72(1):140–146
 55. LeBlanc BW, Albina JE, Reichner JS. The effect of PGG-beta-glucan on neutrophil chemotaxis in vivo. *J Leukoc Biol*. 2006;79(4):667–675
 56. Liang J, Melican D, Cafro L, et al. Enhanced clearance of a multiple antibiotic resistant *Staphylococcus aureus* in rats treated with PGG-glucan is associated with increased leukocyte counts and increased neutrophil oxidative burst activity. *Int J Immunopharmacol*. 1998;20(11):595–614
 57. Novak N, Haberstick J, Bieber T, Allam JP. The immune privilege of the oral mucosa. *Trends Mol Med*. 2008;14(5):191–198
 58. Li LH, Zhang XP, Lv S, et al. Cross-sectional surveys and subtype classification of human Blastocystis isolates from four epidemiological settings in China. *Parasitol Res*. 2007;102(1):83–90
 59. Long HY, Handschack A, König W, Ambrosch A. Blastocystis hominis modulates immune responses and cytokine release in colonic epithelial cells. *Parasitol Res*. 2001;87(12):1029–1030

(Continued from first page)

PEDIATRICS (ISSN Numbers: Print, 0031-4005; Online, 1098-4275).

Copyright © 2014 by the American Academy of Pediatrics

FINANCIAL DISCLOSURE: The study products were provided by Mead Johnson Nutrition. Drs Liu and Scalabrin and Ms Zhuang work in Clinical Research, Department of Medical Affairs at Mead Johnson Nutrition. Drs Li and Jin have no financial relationships relevant to this article to disclose.

FUNDING: This study was funded by Mead Johnson Nutrition.

POTENTIAL CONFLICT OF INTEREST: Drs Liu and Scalabrin and Ms Zhuang work in Clinical Research, Department of Medical Affairs at Mead Johnson Nutrition. The other authors have indicated they have no potential conflicts of interest to disclose.

COMPANION PAPER: A companion to this article can be found on page e1740, online at www.pediatrics.org/cgi/doi/10.1542/peds.2014-0883.

Follow-up Formula Consumption in 3- to 4-Year-Olds and Respiratory Infections: An RCT

Fei Li, Xingming Jin, Bryan Liu, Weihong Zhuang and Deolinda Scalabrin
Pediatrics 2014;133:e1533

DOI: 10.1542/peds.2013-3598 originally published online May 19, 2014;

Updated Information & Services

including high resolution figures, can be found at:
<http://pediatrics.aappublications.org/content/133/6/e1533>

References

This article cites 56 articles, 8 of which you can access for free at:
<http://pediatrics.aappublications.org/content/133/6/e1533#BIBL>

Subspecialty Collections

This article, along with others on similar topics, appears in the following collection(s):

Nutrition

http://www.aappublications.org/cgi/collection/nutrition_sub

Allergy/Immunology

http://www.aappublications.org/cgi/collection/allergy:immunology_sub

Permissions & Licensing

Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:

<http://www.aappublications.org/site/misc/Permissions.xhtml>

Reprints

Information about ordering reprints can be found online:
<http://www.aappublications.org/site/misc/reprints.xhtml>

American Academy of Pediatrics

DEDICATED TO THE HEALTH OF ALL CHILDREN™



PEDIATRICS®

OFFICIAL JOURNAL OF THE AMERICAN ACADEMY OF PEDIATRICS

Follow-up Formula Consumption in 3- to 4-Year-Olds and Respiratory Infections: An RCT

Fei Li, Xingming Jin, Bryan Liu, Weihong Zhuang and Deolinda Scalabrin
Pediatrics 2014;133:e1533

DOI: 10.1542/peds.2013-3598 originally published online May 19, 2014;

The online version of this article, along with updated information and services, is located on the World Wide Web at:

<http://pediatrics.aappublications.org/content/133/6/e1533>

Pediatrics is the official journal of the American Academy of Pediatrics. A monthly publication, it has been published continuously since 1948. Pediatrics is owned, published, and trademarked by the American Academy of Pediatrics, 141 Northwest Point Boulevard, Elk Grove Village, Illinois, 60007. Copyright © 2014 by the American Academy of Pediatrics. All rights reserved. Print ISSN: 1073-0397.

American Academy of Pediatrics

DEDICATED TO THE HEALTH OF ALL CHILDREN™

